News | July 05, 2023
Cipla bags sustainable companies rankings for 2022-23
Cipla has a robust governance model focused on sustainability
Cipla has a robust governance model focused on sustainability
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers
Cipla has received 8 inspectional observations in Form 483
Point-of-Care solution to facilitate clinicians in quick and effective decision making
Cipla and Ethris partner for the development of mRNA-based therapies
_256_384.png)
Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection.
Government of India has granted a patent for invention entitled "An improved safe process for the preparation of Sartan drugs of Formula I".
Subscribe To Our Newsletter & Stay Updated
